Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?
The study highlights gaps in the management of ASCVD in Australian general practice, including the lack of monitoring of LDL-C levels, under-prescription of proven LLT, and increasingly poor adherence and persistence with LLT over time.
Authors
- Charlotte Hespe (ORCID: https://orcid.org/0000-0002-4582-7728)
- Danny Liew (ORCID: https://orcid.org/0000-0002-0131-623X)
- Mohammed M. Rahman (ORCID: https://orcid.org/0000-0003-2229-5121)
- Andrew Tonkin (ORCID: https://orcid.org/0000-0001-5291-0610)
- R. Santani
- C Sciascia
- Gerald F. Watts (ORCID: https://orcid.org/0000-0003-2276-1524)
- Ralph Audehm (ORCID: https://orcid.org/0000-0001-9136-8772)
- Anna Williamson
Institutions
- Novartis (Switzerland) (CH)
- The University of Melbourne (AU)
- Royal Perth Hospital (AU)
- IQVIA (United Kingdom) (GB)
- Monash Health (AU)
- IQ Solutions (US)
- Monash University (AU)
- The University of Adelaide (AU)
- The University of Notre Dame Australia (AU)
Publication Details
- Journal
- Heart Lung and Circulation
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.hlc.2025.07.012
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Australia